Tzield (teplizumab) represents an important shift in Type 1 diabetes care, moving beyond insulin replacement to disease modification.
The therapy is designed to help preserve remaining beta-cell function by targeting the autoimmune process behind the disease.
According to the infographic, the Phase 3 PROTECT trial showed significant benefits in children and adolescents recently diagnosed with Stage 3 T1D.
This expanded FDA indication highlights Tzield’s potential to slow disease progression and protect natural insulin production.